NuSirt Biopharma
Nusirt is a research organization focused on exploring the interactions and effects of compounds like leucine, metformin, sildenafil, and others on metabolic health, insulin sensitivity, lipid metabolism, and related conditions such as non-alcoholic fatty liver disease and obesity. The organization conducts various scientific studies and abstracts to advance understanding in these areas.
Industries
Nr. of Employees
small (1-50)
NuSirt Biopharma
Patents
Products
Amino-acid plus vitamin nutraceutical formulation
Oral nutritional formulation combining a branched-chain amino acid with vitamin B6 evaluated for effects on fat oxidation, oxidative/inflammatory stress, body weight and composition in overweight and obese subjects.
Combination therapy candidate (amino acid + biguanide + PDE5 inhibitor)
Therapeutic candidate combining an amino acid with an anti-hyperglycemic agent and a phosphodiesterase-5 inhibitor evaluated for weight reduction and improvement of metabolic parameters in adults and for regression of hepatic lipid accumulation in animal models.
Amino-acid plus vitamin nutraceutical formulation
Oral nutritional formulation combining a branched-chain amino acid with vitamin B6 evaluated for effects on fat oxidation, oxidative/inflammatory stress, body weight and composition in overweight and obese subjects.
Combination therapy candidate (amino acid + biguanide + PDE5 inhibitor)
Therapeutic candidate combining an amino acid with an anti-hyperglycemic agent and a phosphodiesterase-5 inhibitor evaluated for weight reduction and improvement of metabolic parameters in adults and for regression of hepatic lipid accumulation in animal models.
Services
Design and conduct of mouse studies for obesity, hyperlipidemia and fatty liver with endpoints including weight, hepatic lipid accumulation and inflammatory markers.
Use of myotube and adipocyte models to measure mitochondrial biogenesis and AMPK–SIRT1 signalling and to evaluate effects on insulin sensitivity and lipid metabolism.
Small human studies assessing body weight, composition, glycemic control and metabolic biomarkers for nutritional and combination interventions.
Design and conduct of mouse studies for obesity, hyperlipidemia and fatty liver with endpoints including weight, hepatic lipid accumulation and inflammatory markers.
Use of myotube and adipocyte models to measure mitochondrial biogenesis and AMPK–SIRT1 signalling and to evaluate effects on insulin sensitivity and lipid metabolism.
Small human studies assessing body weight, composition, glycemic control and metabolic biomarkers for nutritional and combination interventions.
Expertise Areas
- Metabolic disease research (obesity, hyperlipidemia, NAFLD/NASH)
- Nutraceutical formulation and evaluation
- Preclinical in vivo and in vitro pharmacology
- Mechanistic signalling pathway research (AMPK–SIRT1)
Key Technologies
- Rodent metabolic disease models (mouse)
- C2C12 myotube and adipocyte cell culture assays
- Invertebrate lifespan assays (C. elegans)
- AMPK and SIRT1 pathway assays